**Question:** Which of the following is an inhibitor of dihydrofolate reductase?

A. Methotrexate
B. Pyrimethamine
C. Allopurinol
D. Chloroquine

**Correct Answer:** D. Chloroquine

**Core Concept:**
Dihydrofolate reductase (DHFR) is an enzyme involved in the synthesis of purines and pyrimidines, which are essential for DNA replication and cell growth. Inhibition of DHFR leads to a deficiency in these essential building blocks and disrupts cellular processes, ultimately causing cell death.

**Why the Correct Answer is Right:**
Chloroquine is an antimalarial drug primarily targeting the parasite Plasmodium falciparum, which causes severe malaria. However, chloroquine can also inhibit DHFR in humans, leading to a deficiency in tetrahydrofolate (THF), a crucial intermediate in the folate pathway. This inhibition results in impaired DNA synthesis and cell division, ultimately causing cell death.

**Why Each Wrong Option is Incorrect:**

A. Methotrexate: Methotrexate is a folic acid analogue that competitively inhibits DHFR, but it is much more potent than chloroquine and is used specifically for its antifolate effect in cancer chemotherapy and autoimmune diseases.

B. Pyrimethamine: Pyrimethamine is an antifolate drug used to treat malaria and toxoplasmosis. It is a potent inhibitor of DHFR, but it is not as potent as methotrexate and is not used for antimalarial treatment.

C. Allopurinol: Allopurinol is an inhibitor of xanthine oxidase, an enzyme involved in purine catabolism, not DHFR. It is primarily used for the treatment of hyperuricemia and gout.

**Clinical Pearl:**
Chloroquine's inhibition of DHFR is a clinical example of a non-specific pharmacological effect, meaning it interferes with cellular processes beyond its intended target. In contrast, methotrexate, pyrimethamine, and allopurinol are specific inhibitors of DHFR, targeting only the intended enzymes in their respective indications.